KYBORA releases a Chinese version of its website – KYBORA has collaborated with some of the best biotech and pharma companies in China for several years now and has fostered lasting relationships with them. These collaborations have enriched KYBORA’s expertise in the region and have highlighted the immense potential for growth and innovation inherent to […]

Read more

Biopharma investment strategies shift due to IRA – On the last day of BIO’s 2023 Investor Forum, the discussion focused on the Inflation Reduction Act and its impact on biopharma investment decisions, which will now require companies to reevaluate their existing strategies to cover potential scenarios because of the IRA in the next 18 to […]

Read more

Emilienne Kambibi KYBORA is proud to be working with Foundation Rwanda and its incredible team members on a program that empowers second-generation rape survivors of the Rwandan genocide. Emilienne Kambibi, Senior Counselor for Foundation Rwanda, is an advocate for mental health among survivors of the 1994 Genocide against the Tutsi. A survivor herself, she has […]

Read more

Reach Out for Our Complimentary Global Biotech Licensing Readiness Assessment In our complimentary one-hour consultation, our team of seasoned professionals will engage in a Q&A session with you. This complimentary offering is designed to provide you with invaluable insights into the international licensing prospects of your product. We will explore your strategic objectives, the strengths […]

Read more

Developing groundbreaking therapies, commercializing products, and/or finding the right partners are all essential activities for successful biotech companies. These tasks can be challenging and hiring an experienced consultant is often the best course of action. Following are the 8 strategic consulting services KYBORA is most often asked to perform. Click here to download the document.

Read more

Sept. 27, 2023 – The Impact of the Inflation Reduction Act (IRA) on Orphan Drugs – ORPHAN Cures Act introduced to boost new rare disease drug development (https://bio.news/health/orphan-cures-act-introduced-to-boost-new-rare-diseasedrug-development/) | The ORPHAN Cures Act, introduced by lawmakers on Sept. 18, 2023, aims to promote the development of new drugs for rare diseases. This legislation responds to […]

Read more

The biotech industry is characterized by intense competition stemming from scientific breakthroughs, innovative therapies, and cutting-edge technologies. Biotech CEOs encounter various challenges when addressing this competitive environment while positioning their companies for success.Click here to download the document.

Read more

In the intricate landscape of biotechnology, the path to introducing innovative products comes with challenges that require strategic expertise. Overcoming market access and reimbursement barriers is crucial for the successful entry and adoption of transformative solutions by Biotech companies in the US market. Click here to download the document:

Read more

Embarking on the global biotech stage, the allure of the Chinese market beckons with undeniable potential. Yet, the path to licensing biotech products in China has its own set of challenges. The intersection of innovation, regulation, culture, and market dynamics creates a complex tapestry that demands careful navigation. Click here to download the document.

Read more

As a Biotech CEO, steering a company through the dynamic landscape of innovation comes with a unique set of challenges, and at the heart of these challenges lies the intricate realm of Intellectual Property (IP). The biotech sector, where breakthrough discoveries can reshape industries and improve lives, demands akeen understanding of how to preserve, protect, […]

Read more

TYPE & ENTER: